Otsuka Beijing Research

Company snapshot

Otsuka Beijing Research is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia, Autosomal Recessive Polycystic Kidney Disease, Multidrug Resistant Tuberculosis, Phenylketonuria, Immunoglobulin A Nephropathy. NovaPharmaNews links 33 clinical program(s), 1 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (12), phase 1 (7), approved (7).

• 2 approved product(s) across US/EU regulatory metadata.
• 33 active pipeline program(s) linked via ClinicalTrials.gov.
• 33 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Otsuka Beijing Research. Not investment advice.

• deal Jun 5, 2026

  Otsuka kidney drug data and Pfizer AI deal: Biopharma deal tracker

• Peer + 0 momentum

  Vanda Pharmaceuticals Netherlands

  TA overlap score 32

• Peer + 0 momentum

  BioXcel Therapeutics

  TA overlap score 23.4

Recent activity

Latest pipeline, patent, and corporate events for Otsuka Beijing Research.

1. Jun 8, 2026 Clinical update

   20-AVP-786-306 — Phase 3

2. Jun 8, 2026 Clinical update

   156-201-00307 — Phase 3

3. Jun 8, 2026 Clinical update

   VIS171-103 — Phase 1

4. Jun 8, 2026 Clinical update

   JNT517-301 — Phase 3

5. Jun 8, 2026 Clinical update

   323-201-00009 — Phase 1

View all clinical trial activity →

• What is Otsuka Beijing Research?

  Otsuka Beijing Research is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia, Autosomal Recessive Polycystic Kidney Disease, Multidrug Resistant Tuberculosis, Phenylketonuria, Immunoglobulin A Nephropathy. NovaPharmaNews links 33 cli

• Is Otsuka Beijing Research publicly traded?

  Otsuka Beijing Research appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Otsuka Beijing Research develop or market?

  We link 25 drug profile(s) where Otsuka Beijing Research is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/otsuka-novel-products-gmbh#company-drugs.

• What are the latest developments for Otsuka Beijing Research?

  In the last 12 months our linked public records show 33 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Otsuka Beijing Research focus on?

  Otsuka Beijing Research focuses on Schizophrenia, Autosomal Recessive Polycystic Kidney Disease, Multidrug Resistant Tuberculosis based on our analysis of their pipeline programs and drug development activities.